Fate Therapeutics (FATE) Competitors $2.02 -0.06 (-2.88%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FATE vs. ADAP, CLLS, BLUE, ATRA, ALLO, ARDX, BCYC, AVBP, COGT, and MESOShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Adaptimmune Therapeutics (ADAP), Cellectis (CLLS), bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Allogene Therapeutics (ALLO), Ardelyx (ARDX), Bicycle Therapeutics (BCYC), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), and Mesoblast (MESO). These companies are all part of the "medical" sector. Fate Therapeutics vs. Adaptimmune Therapeutics Cellectis bluebird bio Atara Biotherapeutics Allogene Therapeutics Ardelyx Bicycle Therapeutics ArriVent BioPharma Cogent Biosciences Mesoblast Adaptimmune Therapeutics (NASDAQ:ADAP) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability. Which has more volatility and risk, ADAP or FATE? Adaptimmune Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Do insiders & institutionals believe in ADAP or FATE? 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, ADAP or FATE? Adaptimmune Therapeutics has higher revenue and earnings than Fate Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$60.28M2.49-$113.87M-$0.22-2.67Fate Therapeutics$13.45M17.11-$160.93M-$1.65-1.22 Does the MarketBeat Community believe in ADAP or FATE? Fate Therapeutics received 164 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 68.28% of users gave Fate Therapeutics an outperform vote while only 62.95% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% Fate TherapeuticsOutperform Votes48068.28% Underperform Votes22331.72% Do analysts prefer ADAP or FATE? Adaptimmune Therapeutics presently has a consensus target price of $3.16, suggesting a potential upside of 439.12%. Fate Therapeutics has a consensus target price of $6.89, suggesting a potential upside of 241.03%. Given Adaptimmune Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptimmune Therapeutics is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 Does the media prefer ADAP or FATE? In the previous week, Adaptimmune Therapeutics had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 24 mentions for Adaptimmune Therapeutics and 19 mentions for Fate Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.39 beat Fate Therapeutics' score of 0.14 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is ADAP or FATE more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Fate Therapeutics -1,325.43%-45.88%-33.95% SummaryAdaptimmune Therapeutics beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks. Ad WealthPressThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…Follow this link here and enter your email address to sign up… Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.07M$2.93B$5.18B$8.74BDividend YieldN/A1.86%5.18%4.08%P/E Ratio-1.2220.1767.0014.47Price / Sales17.11285.221,269.0586.90Price / CashN/A166.9239.9135.24Price / Book0.644.006.495.93Net Income-$160.93M-$42.42M$120.13M$225.73M7 Day Performance-16.53%-10.63%-5.13%-1.34%1 Month Performance-37.27%-5.81%-2.72%1.15%1 Year Performance-16.87%24.19%31.20%24.02% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.958 of 5 stars$2.02-2.9%$6.89+241.0%-15.1%$230.07M$13.45M-1.22550Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageADAPAdaptimmune Therapeutics2.1705 of 5 stars$0.79-3.6%N/A+17.3%$210.76M$60.28M-2.27449Analyst ForecastAnalyst RevisionNews CoverageCLLSCellectis3.6074 of 5 stars$1.99+4.2%N/A-28.6%$106.17M$9.19M-1.53290Analyst ForecastShort Interest ↓High Trading VolumeBLUEbluebird bio2.895 of 5 stars$0.39-2.5%N/A-89.4%$78.59M$29.50M-0.18323Upcoming EarningsAnalyst DowngradeNews CoverageATRAAtara Biotherapeutics3.8552 of 5 stars$11.67-0.8%N/A-0.1%$57.85M$8.57M-0.30165Earnings ReportAnalyst ForecastNews CoverageALLOAllogene Therapeutics2.6654 of 5 stars$2.84-8.1%N/A-19.2%$647.89M$90,000.00-1.82232Analyst ForecastShort Interest ↓News CoverageGap UpARDXArdelyx4.0487 of 5 stars$4.59-6.1%N/A+23.3%$1.16B$124.46M-15.30267Short Interest ↑Analyst RevisionGap UpBCYCBicycle Therapeutics2.8915 of 5 stars$23.42-3.7%N/A+55.8%$1.16B$26.98M-7.12240Insider SellingShort Interest ↑AVBPArriVent BioPharma1.0349 of 5 stars$32.99-3.9%N/AN/A$1.15BN/A0.0040Analyst ForecastNews CoveragePositive NewsCOGTCogent Biosciences2.7391 of 5 stars$10.38-0.2%N/A+20.6%$1.14BN/A-4.1980Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMESOMesoblast1.5876 of 5 stars$9.95+2.2%N/A+298.4%$1.11B$5.90M0.0080News CoverageGap Down Related Companies and Tools Related Companies Adaptimmune Therapeutics Alternatives Cellectis Alternatives bluebird bio Alternatives Atara Biotherapeutics Alternatives Allogene Therapeutics Alternatives Ardelyx Alternatives Bicycle Therapeutics Alternatives ArriVent BioPharma Alternatives Cogent Biosciences Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FATE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
